320 related articles for article (PubMed ID: 28707587)
21. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
Cronstein BN
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S11-5. PubMed ID: 17708739
[TBL] [Abstract][Full Text] [Related]
22. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-6: Biology, signaling and strategies of blockade.
Schaper F; Rose-John S
Cytokine Growth Factor Rev; 2015 Oct; 26(5):475-87. PubMed ID: 26189695
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic uses of anti-interleukin-6 receptor antibody.
Kang S; Tanaka T; Kishimoto T
Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
[TBL] [Abstract][Full Text] [Related]
26. Measuring the bioactivity of anti-IL-6/anti-IL-6R therapeutic antibodies: presentation of a robust reporter gene assay.
Yu C; Cao J; Wang L; Yang Y; Ni Y; Wang J
Anal Bioanal Chem; 2018 Nov; 410(27):7067-7075. PubMed ID: 30178083
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-6: An Important Mediator of Allograft Injury.
Jordan SC; Ammerman N; Choi J; Kumar S; Huang E; Toyoda M; Kim I; Wu G; Vo A
Transplantation; 2020 Dec; 104(12):2497-2506. PubMed ID: 32235253
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic targeting of the interleukin-6 receptor.
Tanaka T; Narazaki M; Kishimoto T
Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
[TBL] [Abstract][Full Text] [Related]
29. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.
Murakami M; Nishimoto N
Curr Opin Rheumatol; 2011 May; 23(3):273-7. PubMed ID: 21427577
[TBL] [Abstract][Full Text] [Related]
30. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.
Atreya R; Mudter J; Finotto S; Müllberg J; Jostock T; Wirtz S; Schütz M; Bartsch B; Holtmann M; Becker C; Strand D; Czaja J; Schlaak JF; Lehr HA; Autschbach F; Schürmann G; Nishimoto N; Yoshizaki K; Ito H; Kishimoto T; Galle PR; Rose-John S; Neurath MF
Nat Med; 2000 May; 6(5):583-8. PubMed ID: 10802717
[TBL] [Abstract][Full Text] [Related]
31. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan.
Nishimoto N
Clin Rev Allergy Immunol; 2005 Jun; 28(3):221-30. PubMed ID: 16129906
[TBL] [Abstract][Full Text] [Related]
32. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
Paul-Pletzer K
Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666
[TBL] [Abstract][Full Text] [Related]
33. Targeting Interleukin-6 Signaling in Clinic.
Kang S; Tanaka T; Narazaki M; Kishimoto T
Immunity; 2019 Apr; 50(4):1007-1023. PubMed ID: 30995492
[TBL] [Abstract][Full Text] [Related]
34. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
Tanaka T; Narazaki M; Ogata A; Kishimoto T
Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
[TBL] [Abstract][Full Text] [Related]
35. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.
Tanaka T; Narazaki M; Kishimoto T
FEBS Lett; 2011 Dec; 585(23):3699-709. PubMed ID: 21419125
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
37. The paradigm of IL-6: from basic science to medicine.
Naka T; Nishimoto N; Kishimoto T
Arthritis Res; 2002; 4 Suppl 3(Suppl 3):S233-42. PubMed ID: 12110143
[TBL] [Abstract][Full Text] [Related]
38. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?
Maes M; Anderson G; Kubera M; Berk M
Expert Opin Ther Targets; 2014 May; 18(5):495-512. PubMed ID: 24548241
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.
Lane T; Gillmore JD; Wechalekar AD; Hawkins PN; Lachmann HJ
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S46-53. PubMed ID: 26120866
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
